Akan H, Başar M, Dalva I, Başar H
Urology Clinic of Bayindir Medical Center, Ankara, Turkey.
Arch Ital Urol Androl. 1998 Feb;70(1):41-4.
It is known that selective alpha-1 adrenoceptor blockers diminish the symptoms and improve the uroflowmetric parameters in benign prostatic hyperplasia (BPH) by the effect on the dynamic component of BPH. The efficacy of doxazosin, a selective alpha-1 adrenoceptor blocker was evaluated in the treatment of BPH by assessing International Prostate Symptom Score (IPSS) and uroflowmetric parameters. While 24 patients were given doxazosin in a daily dose of 4 mg, 19 patients were given placebo. Assessments of IPSS and uroflowmetric parameters were obtained three weekly periods. After three weeks, the decrease in IPSS was more prominent in doxazosin group when compared to placebo group (47% versus 12% respectively, p < 0.05) but improvement in the uroflowmetric parameters was not different statistically in the two groups (in Qmax 24% versus 16%, for doxazosin and placebo groups respectively, p > 0.05). After six weeks the improvement in IPSS continued and improvement in uroflowmetric parameters in doxazosin group was more evident when compared to placebo group (in Qmax 34% versus 19% respectively, p < 0.05). Objective results of doxazosin treatment in BPH can be observed after sixth week of the treatment although symptomatic effects can start at third week.
已知选择性α-1肾上腺素能受体阻滞剂通过作用于良性前列腺增生（BPH）的动态成分，减轻症状并改善BPH患者的尿流率参数。通过评估国际前列腺症状评分（IPSS）和尿流率参数，评价了选择性α-1肾上腺素能受体阻滞剂多沙唑嗪治疗BPH的疗效。24例患者每日服用4mg多沙唑嗪，19例患者服用安慰剂。在三个为期一周的时间段内对IPSS和尿流率参数进行评估。三周后，与安慰剂组相比，多沙唑嗪组IPSS的下降更为显著（分别为47%和12%，p<0.05），但两组尿流率参数的改善在统计学上无差异（多沙唑嗪组和安慰剂组的最大尿流率分别为24%和16%，p>0.05）。六周后，IPSS的改善持续存在，与安慰剂组相比，多沙唑嗪组尿流率参数的改善更为明显（最大尿流率分别为34%和19%，p<0.05）。虽然症状改善在第三周开始，但多沙唑嗪治疗BPH的客观结果在治疗第六周后才能观察到。
